Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience
, 2, 3, 4, 5, 5, 6, 7, 8, 8, 8, 9, 10, 10, 11, 12, 13, 13, 13, 13, 14, 14, 14, 15, 16, 1, 1, 1, 1, 1, 17, 17, 18, 18, 18, 19, 20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 29, 31, 31, 32, 33, 34, 35, 29, 33, 36, 37, 1, 38
Abstract
Introduction. The aim of this study was to report the course and outcome of SARS-CoV-2 infection in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs) in Poland. A major concern for neurologists worldwide is the course and outcome of SARS-CoV-2 infection in patients with MS treated with different DMTs. Although initial studies do not suggest an unfavourable course of infection in this group of patients, the data is limited.
Materials and methods. This study included 396 MS patients treated with DMTs and confirmed SARS-CoV-2 infection from 28 Polish MS centres. Information concerning patient demographics, comorbidities, clinical course of MS, current DMT use, as well as symptoms of SARS-CoV-2 infection, need for pharmacotherapy, oxygen therapy, and/or hospitalisation, and short-term outcomes was collected up to 30 January 2021. Additional data about COVID-19 cases in the general population in Poland was obtained from official reports of the Polish Ministry of Health.
Results. There were 114 males (28.8%) and 282 females (71.2%). The median age was 39 years (IQR 13). The great majority of patients with MS exhibited relapsing-remitting course (372 patients; 93.9%). The median EDSS was 2 (SD 1.38), and the mean disease duration was 8.95 (IQR 8) years. Most of the MS patients were treated with dimethyl fumarate (164; 41.41%). Other DMTs were less frequently used: interferon beta (82; 20.70%), glatiramer acetate (42; 10.60%), natalizumab (35;8.84%), teriflunomide (25; 6.31%), ocrelizumab (20; 5.05%), fingolimod (16; 4.04), cladribine (5; 1.26%), mitoxantrone (3; 0.76%), ozanimod (3; 0.76%), and alemtuzumab (1; 0.25%). The overall hospitalisation rate due to COVID-19 in the cohort was 6.81% (27 patients). Only one patient (0.3%) died due to SARS-CoV-2 infection, and three (0.76%) patients were treated with mechanical ventilation; 106 (26.8%) patients had at least one comorbid condition. There were no significant differences in the severity of SARS-CoV-2 infection regarding patient age, duration of the disease, degree of disability (EDSS), lymphocyte count, or type of DMT used.
Conclusions and clinical implications. Most MS patients included in this study had a favourable course of SARS-CoV-2 infection. The hospitalisation rate and the mortality rate were not higher in the MS cohort compared to the general Polish population. Continued multicentre data collection is needed to increase the understanding of SARS-CoV-2 infection impact on the course of MS in patients treated with DMTs.
Keywords: multiple sclerosisCOVID-19SARS-CoV-2disease-modifying therapies
References
- Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683–690.
- Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2021 Jan 29).
- Zheng J. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci. 2020; 16(10): 1678–1685.
- Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18): 1775–1776.
- Yachou Y, El Idrissi A, Belapasov V, et al. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020; 41(10): 2657–2669.
- Lechien J, Chiesa-Estomba C, Siati DDe, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. 2020; 277(8): 2251–2261.
- Haider A, Siddiqa A, Ali N, et al. COVID-19 and the Brain: Acute Encephalitis as a Clinical Manifestation. Cureus. 2020; 12(10): e10784.
- Giovannoni G, Hawkes C, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020; 39: 102073.
- Sormani M. An Italian programme for COVID-19 infection in multiple sclerosis. The Lancet Neurology. 2020; 19(6): 481–482.
- Rostami Mansoor S, Ghasemi-Kasman M. Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients. J Med Virol. 2021; 93(3): 1314–1319.
- Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020; 42: 102120.
- Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292–302.
- Thompson A, Banwell B, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018; 17(2): 162–173.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444–1452.
- Raport zakażeń koronawirusem (SARS-CoV-2) - Koronawirus: informacje i zalecen. https://www.gov.pl/web/koronawirus/wykaz-zarazen-koronawirusem-sars-cov-2 (2021 Feb 5).
- StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. https://www.stata.com/support/faqs/resources/citing-software-documentation-faqs/ (2021 Feb 5).
- Czarnowska A, Kapica-Topczewska K, Zajkowska O, et al. Herpesviridae Seropositivity in Patients with Multiple Sclerosis: First Polish Study. Eur Neurol. 2018; 80(5-6): 229–235.
- Czupryna P, Tarasow E, Moniuszko-Malinowska A, et al. MRI and planimetric CT follow-up study of patients with severe tick-borne encephalitis. Infect Dis (Lond). 2016; 48(1): 74–81.
- Castelo-Branco A, Chiesa F, Conte S, et al. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult Scler Relat Disord. 2020; 45: 102420.
- Brola W, Sobolewski P, Flaga S, et al. Increasing prevalence and incidence of multiple sclerosis in Poland. Neurol Neurochir Pol. 2017; 51(1): 82–85.
- Wawrzyniak S, Koziarska D, Kułakowska A, et al. Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients. Neurol Neurochir Pol. 2019; 53(2): 131–137.
- Louapre C, Collongues N, Stankoff B, et al. Covisep investigators. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020; 77(9): 1079–1088.
- Parrotta E, Kister I, Charvet L, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5).
- Capasso N, Palladino R, Montella E, et al. Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. J Clin Med. 2020; 9(12).
- Sepúlveda M, Llufriu S, Martínez-Hernández E, et al. Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit. Neurol Neuroimmunol Neuroinflamm. 2021; 8(2).
- Sahraian MA, Azimi A, Navardi S, et al. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020; 46: 102472.
- REDONE.br – Neuroimmunology Brazilian Study Group Focused on COVID-19 and MS. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. Mult Scler. 2021 [Epub ahead of print]: 1352458520978354.
- Ciampi E, Uribe-San-Martin R, Cárcamo C. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Mult Scler Relat Disord. 2020; 42: 102204.
- Fan M, Qiu W, Bu B, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5).
- Liu Y, Mao B, Liang S, et al. Shanghai Clinical Treatment Experts Group for COVID-19. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020; 55(5).
- Wolff D, Nee S, Hickey NS, et al. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021; 49(1): 15–28.
- Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary disease. Eur J Clin Invest. 2020; 50(10): e13382.
- Zhou Y, Yang Q, Chi J, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021; 37(2): e3377–56.
- Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. 2020; 98: 180–186.
- Grant M, Geoghegan L, Arbyn M, et al. The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. SSRN Electronic Journal. .
- Mycko M. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic — when immunosuppression meets infection? Neurologia i Neurochirurgia Polska. 2020; 54(6): 490–501.
- Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series. Mult Scler Relat Disord. 2020; 42: 102192.
- Sormani MP, De Rossi N, Schiavetti I, et al. Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021; 89(4): 780–789.
- Sharifian-Dorche M, Sahraian MA, Fadda G, et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord. 2021 [Epub ahead of print]; 50: 102800.
- Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al. Secondary progressive multiple sclerosis — from neuropathology to definition and effective treatment. Neurologia i Neurochirurgia Polska. 2020; 54(5): 384–398.
- Loonstra FC, Hoitsma E, van Kempen ZLE, et al. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020; 26(10): 1256–1260.
- Dalla Costa G, Leocani L, Montalban X, et al. RADAR-CNS consortium. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020; 41(7): 1647–1650.
- Haji Abdolvahab M, Moradi-Kalbolandi S, Zarei M, et al. Potential role of interferons in treating COVID-19 patients. Int Immunopharmacol. 2021; 90: 107171.
- Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. Case Medical Research. 2020.
- Ciardi MR, Zingaropoli MA, Pasculli P, et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. J Neuroimmunol. 2020 [Epub ahead of print]; 346: 577323.
